Thursday, September 17, 2020 9:53:31 AM
However, the Company urges shareholders to view this information in context
The context is this...
As of 07/31/19, the number of shares outstanding of our Common Stock was: 385,563,721
Currently, it's 3,058,058,634.
Cash up 2,580% on a sequential quarterly basis, and up over 6,700% annually
We know where the cash comes from. It's not from sales.
Note that, in simple terms, our total liabilities held steady from April to July
True. All their liabilities were incurred prior to April. $3,055,470!
Now, to my original suggestion of releasing current annual revenues for 2010 to compare with 2019's, Lovatt states.....
And we continue to project a potential for over $3 million in sales in 2021. What about 2020?
Recall that revs from 2019 were $2.5. So the "projected" numbers are only slightly better than from two years prior.
I expect nothing but a positive slant to everything an OTC CEO puts out but people need to look closer at what a biased source releases in a pr, which is only meant to instill confidence and enthusiasm.
You can lead a horse to water. But you can't make him get down on one knee and do an Al Jolson impression!
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM